BELTSVILLE, MD and MILAN, ITALY--(Marketwire - 08/09/10) - BioServe and NGC Medical SpA today announced the opening of BioServe-Europe. Based in Milan, Italy BioServe-Europe provides the European life science research industry with a comprehensive range of molecular services, including the processing of new personal genetic tests, high-throughput genotyping, and DNA and RNA extractions. In addition, BioServe-Europe distributes biospecimens from its Global BioRepository and biobank partner network, as well as samples sourced from within the EU.

"The combination of cutting edge genomic services and high-quality biosamples has proven to be a powerful offering for the scientific community in North America. Our recent foray in the EU market, working with NGC Medical, has revealed a similar strong demand for these unique services," said Rama Modali, President, BioServe.

Working with BioServe-Europe, many European scientists will for the first time have access to a single source of biosamples covering most major diseases and comprehensive analytical services to unlock and correlate sample information for their research. These complementary services are crucial to furthering the understanding of disease and the development of new research discoveries and therapies.

Modali added, "The EU market is also quickly adopting new in-vitro diagnostic tests as part of a move to a personalized medicine regime. BioServe-Europe's genomic services have the ability to a key component in the processing and validation of these tests' results."

In April of this year, BioServe began its collaboration with NGC Medical, providing them with a full complement of CLIA-certified personalized genomics services, including DNA extraction, QC DNA, and control DNA for NutriGeneCode™ validation. NutriGeneCode™ is a simple, non-invasive saliva test able to identify 50 of the most significant Single Nucleotide Mutations (SNPs) involved in cellular aging and consequent body response, such as lipid and carbohydrate metabolism, hypertension, inflammation, oxidation and detoxification reactions and DNA repair

Paolo Cremascoli, President and CEO of NGC Medical SpA, said, "Our experience working with BioServe has been overwhelmingly positive. From our vantage point it is clear that offering BioServe's complement of services in Europe will continue to be well received. There is simply a lack of high-quality genomic validation services and tissue samples to support the European research market."

About NGC Medical
With more than 20 years of experience in the Italian health sector, NGC Medical is market leader in building and managing public and private hospital departments, including Interventional Cardiology, Electrophysiology and Interventional Radiology catheterization laboratories, Cardiac Surgery units and Intensive Care units.

Avionord, NGC Medical's airline subsidiary, is the domestic market leader in the transportation of human organs for transplants and patients. NGC Pharma, a division of NGC Medical, has developed a genetic test and a line of food supplements specifically designed to address harmful genetic mutations that includes predisposition, family history, anamnesis and lifestyle. For more information please visit www.ngc.it.